Sökning: onr:"swepub:oai:gup.ub.gu.se/258831" >
High expression of ...
High expression of stromal PDGFR beta is associated with reduced benefit of tamoxifen in breast cancer
-
Paulsson, J. (författare)
-
Ryden, L. (författare)
-
Strell, C. (författare)
-
visa fler...
-
Frings, O. (författare)
-
Tobin, N. P. (författare)
-
Fornander, T. (författare)
-
Bergh, J. (författare)
-
- Landberg, Göran, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för patologi,Sahlgrenska Cancer Center,Institute of Biomedicine, Department of Pathology
-
Stal, O. (författare)
-
Ostman, A. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2016-09-14
- 2017
- Engelska.
-
Ingår i: Journal of Pathology Clinical Research. - : Wiley. - 2056-4538. ; 3:1, s. 38-43
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFR beta is an important regulator of fibroblasts. Experimental studies have linked PDGFR beta-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFR beta-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomised studies analysing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFR beta, which was not observed in the group with high stromal PDGFR beta. In general terms these findings provide novel evidence, derived from analyses of randomised clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFR beta as a marker related to tamoxifen benefit in early breast cancer.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- breast cancer
- tamoxifen
- tumour stroma
- PDGFR beta
- term-follow-up
- growth-factor
- tumor microenvironment
- adjuvant
- tamoxifen
- receptor expression
- resistance
- chemotherapy
- fibroblasts
- sensitivity
- inhibition
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Paulsson, J.
-
Ryden, L.
-
Strell, C.
-
Frings, O.
-
Tobin, N. P.
-
Fornander, T.
-
visa fler...
-
Bergh, J.
-
Landberg, Göran, ...
-
Stal, O.
-
Ostman, A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Patho ...
- Av lärosätet
-
Göteborgs universitet